Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Durect says FDA is reviewing long-lasting surgery pain drug Posidur, with decision due in Feb.
Durect says FDA is reviewing long-lasting surgery pain drug Posidur, with decision due in Feb.
Durect says FDA is reviewing long-lasting surgery pain drug Posidur, with decision due in Feb.
Submitted by
admin
on June 20, 2013 - 11:03am
Source:
Yahoo/AP
News Tags:
Durect
FDA
Posidur
post-surgical pain
Headline:
Durect says FDA is reviewing long-lasting surgery pain drug Posidur, with decision due in Feb.
Do Not Allow Advertisers to Use My Personal information
